Accueil   Diary - News   All news Poxel Announces Positive Results for Thorough QT Safety Clinical Study of Imeglimin

Poxel Announces Positive Results for Thorough QT Safety Clinical Study of Imeglimin

POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for type 2 diabetes, today announced that it has successfully completed a thorough QT/QTc (TQT) cardiac safety study on Imeglimin in 55 healthy subjects. This study assesses a drug’s risk of QT prolongation and its proarrhythmic potential, which is a heart conduction disorder that can cause serious irregular heart rhythms (arrhythmias), and is a standard component of all clinical development programs for new molecular entities.



Read the press release